Another COVID-19 vaccine shows promise

Embargoed until: Publicly released:
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.

Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.

People: This is a study based on research using people.

Interim results of a phase 1-2a trial of a COVID-19 candidate vaccine, Ad26.COV2.S, suggest it can provoke a neutralising antibody response in 90 per cent of recipients 29 days after administration, reaching 100 per cent after 57 days. And white blood cell responses were boosted in 76 - 83 per cent of recipients 14 days after administration. These trials were focused on the vaccine candidate's safety and ability to produce immune responses, and the results suggest it should be developed further, the authors say.

Journal/conference: NEJM

Link to research (DOI): 10.1056/NEJMoa2034201

Organisation/s: Janssen Vaccines and Prevention, the Netherlands

Funder: Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 number, NCT04436276.


  • Massachusetts Medical Society
    Web page
    The URL will go live after the embargo ends

News for:


Media contact details for this story are only visible to registered journalists.